knowledge -WSS

knowledge

author：explore 2025-10-01 20:14:49 - browse：22532

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Amylyx ALS drug failure raises questions and concerns

WSS

In his State of the Union, Biden takes clear aim at 'Big Pharma'

It's time to retire 'poor historian' from clinicians' vocabularies

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

UnitedHealth quietly bought dozens of outpatient centers

When prostate cancer spreads, where it goes matters

Helping hospitals and community health centers plan for resilience

Wikipedia

knowledge

focus

After affirmative action ruling, medical educators look to 'holistic review'

With measles on the rise, a personal story of a devastating disease

Medicare proposal to cover medical devices draws a mixed reaction

RSV shot was 90% effective at preventing hospitalizations in kids

FDA approval of Sarepta Duchenne genetic therapy gives me hope

RSV shot was 90% effective at preventing hospitalizations in kids

Medicare details structure of new drug price negotiation program

When prostate cancer spreads, where it goes matters

Trump demands the U.S. pay no more for drugs than other countries … again

RSV shot was 90% effective at preventing hospitalizations in kids

leisure time

The Readout: Amylyx, Alumis, and Lundbeck drug updates

It's time to retire 'poor historian' from clinicians' vocabularies

When prostate cancer spreads, where it goes matters

UnitedHealth quietly bought dozens of outpatient centers

Criminal prosecution for violating HIPAA: an emerging threat

Case highlights the risks of experimental stem cell therapy

hotspot

focus

focus

Wikipedia